(CCRN) Cross Country Healthcare - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2274831047
CCRN: Nurse Staffing, Allied Staffing, Physician Staffing, Consultative Services
Cross Country Healthcare, Inc. (NASDAQ:CCRN) is a leading provider of healthcare workforce management solutions in the United States. The company operates through two primary segments: Nurse and Allied Staffing, and Physician Staffing. Its Nurse and Allied Staffing segment offers comprehensive talent acquisition and workforce management services, including temporary and permanent placements of nurses, allied professionals, and healthcare leaders. The segment also provides education and in-home care services, as well as outsourcing solutions such as MSP, VMS, and RPO. This division serves a diverse range of healthcare facilities, including hospitals, clinics, schools, and government institutions, under the Cross Country brand.
The Physician Staffing segment, operating under the Cross Country Locums brand, specializes in placing physicians, nurse practitioners, and physician assistants in temporary roles across various healthcare settings. This segment caters to acute and non-acute care facilities, medical groups, and managed care organizations. Cross Country Healthcare has established itself as a trusted partner in addressing staffing challenges in the healthcare industry, leveraging its extensive network and consultative approach to deliver tailored solutions.
From a technical perspective, CCRN is currently trading at $17.27, slightly below its 20-day SMA of $17.98 and 50-day SMA of $18.06. The stocks 200-day SMA of $14.93 indicates a recent upward trend. Average daily volume stands at 443,492 shares, with an ATR of 0.11, suggesting moderate volatility. On the fundamental side, the company has a market cap of $584.22 million, with a forward P/E ratio of 32.89, reflecting investor expectations of future earnings growth. The P/B ratio of 1.38 indicates the stock is trading at a modest premium to its book value, while the negative RoE of -0.42 raises concerns about profitability.
3-Month Forecast: Based on
Additional Sources for CCRN Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CCRN Stock Overview
Market Cap in USD | 523m |
Sector | Healthcare |
Industry | Medical Care Facilities |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2001-10-25 |
CCRN Stock Ratings
Growth 5y | 38.1% |
Fundamental | -38.6% |
Dividend | 0.0% |
Rel. Strength Industry | -8.4 |
Analysts | 3/5 |
Fair Price Momentum | 14.87 USD |
Fair Price DCF | 80.23 USD |
CCRN Dividends
No Dividends PaidCCRN Growth Ratios
Growth Correlation 3m | -33.8% |
Growth Correlation 12m | 7% |
Growth Correlation 5y | 36.6% |
CAGR 5y | 14.93% |
CAGR/Max DD 5y | 0.20 |
Sharpe Ratio 12m | -0.24 |
Alpha | -14.64 |
Beta | 0.44 |
Volatility | 52.54% |
Current Volume | 243.3k |
Average Volume 20d | 447.4k |
As of March 15, 2025, the stock is trading at USD 15.58 with a total of 243,277 shares traded.
Over the past week, the price has changed by -2.20%, over one month by -14.16%, over three months by -13.11% and over the past year by -7.59%.
Probably not. Based on ValueRay Fundamental Analyses, Cross Country Healthcare (NASDAQ:CCRN) is currently (March 2025) not a good stock to buy. It has a ValueRay Fundamental Rating of -38.59 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CCRN as of March 2025 is 14.87. This means that CCRN is currently overvalued and has a potential downside of -4.56%.
Cross Country Healthcare has received a consensus analysts rating of 3.00. Therefor, it is recommend to hold CCRN.
- Strong Buy: 0
- Buy: 0
- Hold: 8
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, CCRN Cross Country Healthcare will be worth about 16.2 in March 2026. The stock is currently trading at 15.58. This means that the stock has a potential upside of +4.24%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 18.6 | 19.4% |
Analysts Target Price | 17.5 | 12.1% |
ValueRay Target Price | 16.2 | 4.2% |